Status:

TERMINATED

EVL Plus Drug to Prevent Variceal Rebleeding

Lead Sponsor:

National Science and Technology Council, Taiwan

Conditions:

Bleeding

Eligibility:

All Genders

20-75 years

Phase:

PHASE4

Brief Summary

Both medications with beta-blockers and isosorbide-5-mononitrate and endoscopic variceal ligation have been proven plausible in the prevention of variceal rebleeding. However, the relative efficacy an...

Detailed Description

Bleeding from esophageal varices is a severe complication of portal hypertension. After initial control of acute variceal bleeding, patients still carry a high risk of rebleeding. Of those do rebleed,...

Eligibility Criteria

Inclusion

  • Acute bleeding from esophageal varices (defined below);
  • the etiology of portal hypertension was cirrhosis; and
  • age was between 20 and 75 years old. The diagnosis of cirrhosis was based on pathology, clinical, biochemical, and sonographic or computed tomographic findings. Acute esophageal variceal bleeding was defined as when blood was directly seen by endoscopy to issue from an esophageal varix, or when patients presented with red color signs on their esophageal varices with blood in esophagus or stomach and no other potential site of bleeding identified.

Exclusion

  • association with hepatocellular carcinoma or other malignancy,
  • association with cerebral vascular accident, uremia, sepsis or other debilitating disease,
  • had history of gastric variceal bleeding,
  • received beta blocker within one month prior to entry,
  • had history of contraindication to the use of beta blockers, such as asthma, heart failure, atrioventricular block, bradycardia (pulse rate \<55/min) or arterial hypotension (systolic blood pressure\<90 mmHg).
  • had history of prior shunt operation, TIPS (transjugular intrahepatic portosystemic stent shunt), EIS or EVL,
  • deep jaundice (serum bilirubin \>10mg/dl),
  • encephalopathy greater than stage II,
  • failure in control of index variceal bleeding,
  • death within 24 hours of admission, or
  • refused to participate in the trial.

Key Trial Info

Start Date :

July 1 2001

Trial Type :

INTERVENTIONAL

End Date :

March 1 2005

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00371943

Start Date

July 1 2001

End Date

March 1 2005

Last Update

September 15 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gin-Ho Lo

Kaohsiung City, Taiwan, 813

EVL Plus Drug to Prevent Variceal Rebleeding | DecenTrialz